GSK Shares Soar on $2.2B Zantac Lawsuit Settlement
Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of up to $2.2 billion
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication, Zantac.
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer.
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company.
GSK shares jump on $2.2 billion Zantac settlement
By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
Thanks largely to news of a crucial legal settlement, GSK (NYSE: GSK) was one of the better-performing big pharma stocks on ...
GSK plc (NYSE:GSK) Shares Purchased by SG Americas Securities LLC
SG Americas Securities LLC increased its position in GSK plc (NYSE:GSK – Free Report) by 167.3% in the third quarter, ...
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...
Nasdaq6d
Here's Why GSK (GSK) is a Strong Value Stock
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GSK should be on investors' short list. Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in ...
GSK (NYSE:GSK) Sees Unusually-High Trading Volume – Still a Buy?
GSK plc (NYSE:GSK – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 10,740,675 shares changed hands during mid-day trading, an increase of 196% from the previous ...
news.stocktradersdaily4d
How to Take Advantage of moves in (GSK)
When Investors Make Decisions in Gsk Plc American Depositary Shares (each Representing Two) GSK Opportunities Surface ...
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...
Jim Cramer Says GSK plc (GSK) ‘Goes Higher’
We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...